Top ▲
Target not currently curated in GtoImmuPdb
Target id: 1968
Nomenclature: cyclin dependent kinase 15
Abbreviated Name: CDK15
Family: TAIRE subfamily
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 435 | 2q33.1 | CDK15 | cyclin dependent kinase 15 | |
Mouse | - | 433 | 1 C1.3 | Cdk15 | cyclin dependent kinase 15 | |
Rat | - | 437 | 9q31 | Cdk15 | cyclin-dependent kinase 15 |
Previous and Unofficial Names |
ALS2CR7 | PFTAIRE protein kinase 2 | PFTAIRE2 | Cell division protein kinase 15 | frizzled family receptor 7 | cyclin-dependent kinase 15 |
Database Links | |
Alphafold | Q96Q40 (Hs), Q3V3A1 (Mm) |
BRENDA | 2.7.11.22 |
ChEMBL Target | CHEMBL5856 (Hs) |
Ensembl Gene | ENSG00000138395 (Hs), ENSMUSG00000026023 (Mm), ENSRNOG00000022899 (Rn) |
Entrez Gene | 65061 (Hs), 271697 (Mm), 301440 (Rn) |
Human Protein Atlas | ENSG00000138395 (Hs) |
KEGG Enzyme | 2.7.11.22 |
KEGG Gene | hsa:65061 (Hs), mmu:271697 (Mm), rno:301440 (Rn) |
Pharos | Q96Q40 (Hs) |
RefSeq Nucleotide | NM_001261435 (Hs), NM_001033373 (Mm), XM_237191 (Rn) |
RefSeq Protein | NP_631897 (Hs), NP_001028545 (Mm), XP_237191 (Rn) |
UniProtKB | Q96Q40 (Hs), Q3V3A1 (Mm) |
Wikipedia | CDK15 (Hs) |
Enzyme Reaction | ||||
|
DiscoveRx KINOMEscan® screen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform. http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan Reference: 1-2 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Target used in screen: PFTAIRE2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Displaying the top 10 most potent ligands View all ligands in screen » |
1. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol, 29 (11): 1046-51. [PMID:22037378]
2. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem Biol, 17 (11): 1241-9. [PMID:21095574]
TAIRE subfamily: cyclin dependent kinase 15. Last modified on 20/03/2013. Accessed on 24/01/2025. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=1968.